Thin colorectal cancer patients have shorter survival than obese patients
the ONA take:
According to new findings presented today at the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain, researchers from Duke University School of Medicine in Durham, North Carolina, have found that thin patients with colorectal cancer have shorter survival than obese patients.
For the study, researchers analyzed data from 6,128 patients who had been treated for untreated metastatic colorectal cancer. All patients received bevacizumab plus chemotherapy.
Researchers found that patients with a body mass index (BMI) between 20 and 24.9 survived a mean of 21.1 after treatment initiation compared with 23.5 months for those with a BMI of 25 to 29 and 24 months for those with a BMI of 30 to 35.
"Contrary to our hypothesis, patients who had the lowest BMI were at risk for having the shortest survival," said lead author Yousuf Zafar, M.D., associate professor of medicine at Duke University. "In this case, patients with the lowest body weight—people who had metastatic colon cancer and a BMI of less than 25—were at the highest risk."
The findings do not mean that being overweight is protective for patients with colorectal cancer undergoing treatment, but rather there could be an underlying mechanism that put thinner patients at an increased risk for poor outcomes.
Thin patients with colorectal cancer have shorter survival than obese patients.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|